Off-the-shelf and on the de­cline: Adicet Bio’s shares halved af­ter PhI look at cell ther­a­py

Adicet Bio’s stock price was halved on Tues­day morn­ing as in­vestors tanked the biotech’s shares $ACET fol­low­ing a look at Phase I da­ta on its off-the-shelf cell ther­a­py.

The Cal­i­for­nia biotech’s al­lo­gene­ic cell ther­a­py is be­ing in­ves­ti­gat­ed in pa­tients with ag­gres­sive forms of B-cell non-Hodgkin’s lym­phoma, and half of them had pre­vi­ous­ly failed on an au­tol­o­gous CAR-T ther­a­py, a sign that more treat­ment op­tions are need­ed be­yond the first-gen­er­a­tion ap­proach. But Adicet’s da­ta drop af­ter Mon­day’s clos­ing bell — and talk of a lat­er-than-pre­vi­ous­ly guid­ed piv­otal tri­al — sent shares spi­ral­ing and led an­a­lysts to ques­tion the dura­bil­i­ty po­ten­tial of ADI-001.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER